NCT04666688 - LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 12, 2024

Study Completion Date

December 12, 2024

Conditions

Metastatic CancerSolid TumorPancreatic CancerUrothelial CarcinomaHead and Neck CancerColorectal Cancer

Interventions

DRUG

LYT-200

monoclonal antibody (mAb), targeting galectin-9 protein

DRUG

Tislelizumab

anti-PD-1 monoclonal antibody

DRUG

Gemcitabine/nab-paclitaxel

chemotherapy

Trial Locations (12)

10027

Columbia University, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

34232

Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Tennessee Oncology, Nashville

49546

South Texas Accelerated Research Therapeutics, Grand Rapids

77030

University of Texas, M.D. Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, San Antonio

80045

University of Colorado Hospital, Denver

80218

Sarah Cannon Research Institute at Health One, Denver

90095

UCLA, Los Angeles

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

lead

PureTech

INDUSTRY